Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO1996021431 - REDUCTION DES FORCES ELECTROSTATIQUES ENTRE ADSORBATS DE TRISILICATE DE MAGNESIUM

Numéro de publication WO/1996/021431
Date de publication 18.07.1996
N° de la demande internationale PCT/US1995/014858
Date du dépôt international 14.11.1995
Demande présentée en vertu du Chapitre 2 27.07.1996
CIB
A61K 9/14 2006.01
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
9Préparations médicinales caractérisées par un aspect particulier
14à l'état particulaire, p.ex. poudres
CPC
A61K 9/143
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
143with inorganic compounds
Y10S 514/949
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
514Drug, bio-affecting and body treating compositions
949Naturally derived clay, e.g. bentonite
Y10S 514/951
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
514Drug, bio-affecting and body treating compositions
951Powders, granules or particles of specified mesh or particle size
Y10S 514/961
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
514Drug, bio-affecting and body treating compositions
96Significant, tablet formulation, e.g. designated excipient, disintegrant, glydent or lubricant
961Binder therefor
Y10S 514/974
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
514Drug, bio-affecting and body treating compositions
974Containing designated ingredient to reduce noxious effects of active ingredient, e.g. taste masking, odor reducing
Déposants
  • WARNER-LAMBERT COMPANY [US]/[US]
Inventeurs
  • GARAY, Felipe
  • LECH, Stanley
  • OEHLING, Mark
Mandataires
  • RYAN, M., Andrea
  • MANSMANN, Ivo
Données relatives à la priorité
08/370,92710.01.1995US
Langue de publication anglais (EN)
Langue de dépôt anglais (EN)
États désignés
Titre
(EN) REDUCTION OF ELECTROSTATIC FORCES BETWEEN MAGNESIUM TRISILICATE ADSORBATES
(FR) REDUCTION DES FORCES ELECTROSTATIQUES ENTRE ADSORBATS DE TRISILICATE DE MAGNESIUM
Abrégé
(EN)
A medicament adsorbate containing corn syrup having contained therein from about 10 to about 90 % by weight of the adsorbate of a medicament drug, a magnesium trisilicate having a surface area of at least 400 m2/g and having a structure with multiple interstitial spaces, and having adsorbed therein from about 0.5 to about 30 % by weight of the adsorbate of a medicament drug, wherein the medicament drug is an antihistamine. A reduction in the electrostatic forces between adsorbates is experienced due to the particle size of the adsorbate being in the range greater than 40 to about 800 um, most of the adsorbates prepared being a particle size greater than 150 um, which allows for better processing.
(FR)
On décrit un adsorbsat médicamenteux contenant du sirop de maïs ayant contenu environ 10 à 90 % en poids d'adsorbat d'un médicament, un trisilicate de magnésium ayant une surface d'au moins 400 m2/g et une structure contenant de multiples espaces interstitiels et ayant adsorbé environ 0,5 à 30 % en poids de l'adsorbat d'un médicament, ce dernier étant un antihistaminique. La réduction des forces électrostatiques entre les adsorbats s'effectue grâce à la taille des particules de l'adsorbat, qui se trouve dans la plage comprise entre plus de 40 et environ 800 mu, la plupart des adsorbats préparés ayant une taille de particules supérieure à 150 mu, ce qui permet un meilleur traitement.
Également publié en tant que
NZ297255
Dernières données bibliographiques dont dispose le Bureau international